Table 2 Baseline characteristics of study population relative to sex and mortality status at 30 days following the qualifying positive SARS-CoV-2 test
Characteristic | Men | Women | ||||
|---|---|---|---|---|---|---|
No death within 30 days (n = 24,669) | Death within 30 days (n = 225) | Mortality rate (%) in men with condition | No death within 30 days (n = 27,343) | Death within 30 days (n = 192) | Mortality rate (%) in women with condition | |
Age in years, median (Q1, Q3) | 41 (29, 56) | 81 (68, 88) | - | 43 (29, 56) | 86 (79, 93) | - |
Major cardiovascular disease (recent myocardial infarction* or lifetime history of heart failure) | 569 (2.3%) | 64 (28.4%) | 10.1% | 496 (1.8%) | 56 (29.2%) | 10.1% |
Diabetes | 3,558 (14.4%) | 99 (44.0%) | 2.7% | 3,620 (13.2%) | 59 (30.7%) | 1.6% |
Hypertension | 5,810 (23.6%) | 177 (78.7%) | 3.0% | 6,123 (22.4%) | 165 (85.9%) | 2.6% |
Recent cancer* | 380 (1.5%) | 23 (10.2%) | 5.7% | 544 (2.0%) | 19 (9.9%) | 3.4% |
Chronic obstructive pulmonary disease (COPD) | 1,165 (4.7%) | 65 (28.9%) | 5.3% | 1,178 (4.3%) | 58 (30.2%) | 4.7% |
Stage 4/5 chronic kidney disease (CKD)†| 156 (0.6%) | 27 (12.0%) | 14.8% | 139 (0.5%) | 28 (14.6%) | 16.8% |
Undetermined CKD status | 9,629 (39.0%) | 6 (2.7%) | 0.1% | 8,063 (29.5%) | 7 (3.6%) | 0.1% |
Chronic dialysis | 80 (0.3%) | 11 (4.9%) | 12.1% | 48 (0.2%) | 7 (3.6%) | 12.7% |
Frailty‡ | 671 (2.7%) | 103 (45.8%) | 13.3% | 904 (3.3%) | 116 (60.4%) | 11.4% |